Anthera Pharmaceuticals Announces Emerging Data from Phase 2 Open-Label Extension Study to be Presented at the ACR/ARHP 2013

   Anthera Pharmaceuticals Announces Emerging Data from Phase 2 Open-Label
Extension Study to be Presented at the ACR/ARHP 2013 Annual Scientific Meeting

PR Newswire

HAYWARD, Calif., Sept. 25, 2013

HAYWARD, Calif., Sept. 25, 2013 /PRNewswire/ -- Anthera Pharmaceuticals
(NASDAQ: ANTH), a biopharmaceutical company focused on developing and
commercializing products to treat autoimmune diseases, announced today that
emerging data from its Phase 2b PEARL-SC study and subsequent Open-Label
Extension study will be presented by Dr. Richard Furie at the 2013 Annual
Scientific Meeting of the American College of Rheumatology and the Association
of Rheumatology Health Professionals (ACR/ARHP).

Two abstracts, an oral presentation and a poster, will summarize interim
findings from analyses of the Open-Label Extension study pertaining to the
durability of effects of blisibimod over 52 weeks on renal biomarkers,
including proteinuria and Complement C3, and serum immunoglobulins, including
IgG and IgM.

The immunoglobulins IgG and IgA are thought to play a significant role in IgA
nephropathy (IgAN). According to the Journal of Clinical Investigation, IgAN
is characterized by immune complexes composed of galactose-deficient IgA1
(immunogenic IgA) and a glycan-specific IgG antibody that deposit in the
kidneys.

"IgG and immunogenic IgA, when combined, form a complex that deposits in the
kidney leading to a slow, insidious loss of kidney function," said Dr.
Jonathan Barratt, an IgA nephropathy specialist from the University of
Leicester. "Any data that demonstrate a decrease in serum immunoglobulin
levels provide further evidence for blisibimod's potential effectiveness in
treating patients with IgA nephropathy."

"We're very excited to be able to present data which provides additional
insight into the role of blisibimod administration on immunoglobulin levels in
patients with autoimmune diseases. They are a key component of what we
discussed with the FDA and are exploring in the BRIGHT-SC clinical trial,"
said Dr. Colin Hislop, Anthera's Chief Medical Officer. "The pathology of IgA
nephropathy is heavily centered on the abundance of these proteins."

Oral Presentation: "Effects of Blisibimod, an Inhibitor of B Cell Activating
Factor, on Serum Immunoglobulins and Infection Risk in Patients with Systemic
Lupus Erythematosus: Observations from the Placebo-Controlled PEARL-SC and
Open-Label Extension Studies": Clinical Aspects and Treatment: Biologic
Therapy (2:30PM-4:00PM, October 28^th)

Poster: "Effects of Chronic Treatment with Blisibimod, an Inhibitor of B Cell
ActivatingFactor, on Renal and Inflammation Biomarkers in Patients with
Systemic Lupus Erythematosus:Observations from the Placebo-Controlled
PEARL-SC and Open-Label Extension Studies": Clinical Aspects Poster II:
Central Nervous System Manifestation (8:30AM – 4:00PM, October 28^th)

Anthera will be hosting a breakout session following the presentations by Dr.
Furie. Please contact ir@anthera.com for the event details.

About Blisibimod and PEARL-SC

Anthera is developing blisibimod, a selective inhibitor of B-cell activating
factor (BAFF), to explore its clinical utility in various autoimmune diseases
including systemic lupus erythematosus (SLE) and IgA nephropathy. Blisibimod
is a novel fusion protein, or peptibody, and is distinct from an antibody.
Anthera owns worldwide rights to blisibimod in all potential indications.
BAFF, also known as BLyS (B lymphocyte stimulator), is a tumor necrosis family
member and is critical to the development, maintenance and survival of
B-cells. B-cells represent a critical component of human immune response to
infection and other pathogens.However, abnormal elevations of B-cells and
BAFF may lead to an overactive immune response which may damage normal healthy
tissues and organ systems.Multiple clinical studies with BAFF antagonists
have reported the potential benefit of BAFF inhibitors in treating patients
with lupus and rheumatoid arthritis.

In April 2012, Anthera completed the PEARL-SC Phase 2b clinical study to
evaluate the efficacy and safety of subcutaneous blisibimod in patients with
active and seropositive lupus. In June and July of 2012 Anthera announced
results from PEARL-SC which led to the initiation of a Phase 3 registration
plan utilizing the 200mg weekly dose of blisibimod in patients who were
afflicted with active lupus despite receiving corticosteroids.

About Anthera Pharmaceuticals

Anthera Pharmaceuticals is a biopharmaceutical company focused on developing
and commercializing products to treat serious diseases associated with
inflammation and autoimmune disorders.

Safe Harbor Statement

Any statements contained in this press release that refer to future events or
other non-historical matters, including statements that are preceded by,
followed by, or that include such words as "estimate," "intend," "anticipate,"
"believe," "plan," "goal," "expect," "project," or similar statements, are
forward-looking statements made pursuant to the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. Such statements are based on
the Company's expectations as of the date of this press release and are
subject to certain risks and uncertainties that could cause actual results to
differ materially, including but not limited to the risks and uncertainties
associated with market conditions, as well as those set forth in the Company's
public filings with the SEC, including the Company's Annual Report on Form
10-K for the year ended December 31, 2012 and Quarterly Report on Form 10-Q
for the quarter ended June 30th, 2013. The Company disclaims any intent or
obligation to update any forward-looking statements, whether because of new
information, future events or otherwise, except as required by applicable law.

CONTACT: Dennis Lutz of Anthera Pharmaceuticals, Inc., dlutz@anthera.com or
510.856.5598.

SOURCE Anthera Pharmaceuticals, Inc.

Website: http://www.anthera.com